Argentis – CHP

arGentis receives U.S Patent for Arthritis Treatment July 5, 2016

and

Commercial Healthcare Partners attended the Biotech Showcase partnering meeting associated with the JP Morgan healthcare conference held in San Francisco January 11-13, 2016.
More than 30 meetings were held with potential partners as well as pharmaceutical and biotechnology companies.
As a result of these meetings, the following opportunities were identified:
•    Major pharmaceutical company looking to in-license products in all stages of development in the respiratory, autoimmune and allergy therapeutic areas
•    Orphan drug company in Japan seeking to in-license late stage assets for Japanese markets. Current portfolio of products include dysmenorrhea, patent ductus arteriosus and Wilson’s disease
•    Japanese pharma company is seeking products to replace the loss of its flagship product. Areas of interest include CNS, renal disease, behavioral medicine as well as a broad spectrum of additional pharma products
•    Japanese company interested in in-licensing assets for the treatment of autoimmune diseases including arthritis, MS, hepatitis and other chronic diseases. Will consider early stage compounds.
•    Marketing consultant with connections in the middle east will evaluate approved and late stage products for distribution in middle eastern markets.
•    Chinese company interested in buying manufacturing facility in the U.S. Also interested in in-licensing products for the Chinese market including medical devices
•    Well known Indian pharmaceutical manufacturer looking for ANDAs and 505(b)(2) assets for the U.S. market.
•    Chinese pharma company desires to identify products for the Chinese and U.S. markets. Therapeutic areas of interest include oncology, Infectious Disease, auto-immune, neurology/pain management, diabetes, and metabolic disease
•    U.S. based company offers Ex U.S. rights to CNS and GI products
•    Chinese based consulting company looking to make an acquisition in the U.S.
•    U.S. company interested looking to in-license products in the pain management space including opioid based products
•    Large pharma company seeks products in the auto-immune space for the UK market
•    Korean company seeks to in-license pharma products for the Korean market.
•    Pharma company interested in in-licensing products for the treatment of gout, arthritic diseases, and pain management.
•    Israeli company wants to add late stage assets in multiple therapeutic areas for the U.S. market. Will also consider an acquisition.
•    Family owned pharma company wishes to identify assets that are designated as orphan drugs and are undergoing 505(b)(2) regulatory review. Will consider an acquisition.

Questions? Feel free to contact us!

Call (615) 887-3847

We appreciate your interest! Please get in touch and we will contact you directly.

Services and Partnership Opportunities

Pharmaceutical BD&L
Pharma BD&L
Pharmaceutical business development
ANDAs for sale
ANDA licensing
Pharmaceutical in-licensing

Pharmaceutical out-licensing
505(b)(2) for sale
Pharma in-licensing
Pharma out-licensing
Oncology company for sale
Oncology sales force

Pharma distribution deals
Branded generics for sale
Pharmaceutical partnering companies
Pharmaceutical development deals
Pharma commercialization consulting
Head and neck cancer assets available for licensing

Pharmaceutical deal arrangers
Pharma manufacturing facilities finders
Pharmaceutical authorized generic products available

Commercial Healthcare Partners

DISCLAIMER

The information contained in this website is for general information purposes only. The information is provided by Commercial Healthcare Partners and while we endeavor to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.

About | Services| Contact | Privacy Policy